Robert W. Baird Raises IQVIA (NYSE:IQV) Price Target to $287.00

IQVIA (NYSE:IQV) had its target price boosted by analysts at Robert W. Baird from $252.00 to $287.00 in a report released on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s target price would suggest a potential upside of 16.98% from the stock’s previous close.

A number of other brokerages also recently issued reports on IQV. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Morgan Stanley reiterated an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Mizuho upped their price target on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Barclays reiterated an “overweight” rating on shares of IQVIA in a report on Tuesday. Finally, Evercore reissued an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a research report on Wednesday, April 8th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $227.94.

IQVIA Stock Up 15.1%

Shares of NYSE:IQV opened at $245.34 on Wednesday. The stock has a market capitalization of $40.95 billion, a P/E ratio of 30.40, a price-to-earnings-growth ratio of 1.91 and a beta of 1.20. IQVIA has a 12-month low of $154.50 and a 12-month high of $247.72. The stock’s 50-day moving average price is $190.47 and its 200-day moving average price is $186.86. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter in the previous year, the company posted $2.81 earnings per share. The business’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts anticipate that IQVIA will post 11.57 earnings per share for the current year.

IQVIA declared that its board has initiated a stock repurchase program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Institutional Trading of IQVIA

Institutional investors have recently added to or reduced their stakes in the business. Ameliora Wealth Management Ltd. purchased a new position in shares of IQVIA in the fourth quarter worth $25,000. International Assets Investment Management LLC bought a new stake in shares of IQVIA during the 4th quarter valued at $27,000. Gilpin Wealth Management LLC purchased a new stake in shares of IQVIA in the 4th quarter worth $27,000. CrossGen Wealth LLC bought a new position in IQVIA in the 4th quarter worth $28,000. Finally, Activest Wealth Management lifted its position in IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 118 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q2 earnings and revenue beat expectations: IQVIA reported adjusted earnings of $3.15 per share, above the $3.02-$3.03 consensus, while revenue reached $4.37 billion versus approximately $4.30 billion expected. Revenue increased 8.7% year over year, and earnings rose from $2.81 per share in the prior-year quarter. IQVIA Reports Second-Quarter 2026 Results
• Positive Sentiment: Raised 2026 guidance: IQVIA now expects full-year earnings of $12.80-$13.00 per share, above the $12.57 analyst consensus. Revenue guidance of $17.3 billion-$17.5 billion was also reaffirmed or modestly raised relative to expectations. IQV Q2 Earnings Beat Estimates on R&D Bookings, Guidance Raised
• Positive Sentiment: Strong demand indicators: Record research-and-development bookings, a growing backlog and broad-based business growth suggest continued demand from pharmaceutical and biotechnology customers. Management cited stronger clinical research demand as a key factor behind the improved outlook. IQVIA Stocks Rises on 2Q Gains, Ballooning Backlog
• Neutral Sentiment: Management’s earnings call and additional metric analysis provided further detail on the quarter, including performance relative to estimates and the company’s updated growth trajectory. IQVIA Q2 2026 Earnings Call Transcript

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.